DOCSLIB.ORG

In Primary Immunodeficiencies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
In Primary Immunodeficiencies IN PRIMARY IMMUNODEFICIENCIES APECED: Is this a model for failure of T-cell and B-cell tolerance? Nicolas Kluger, Annamari Ranki and Kai Krohn Journal Name: Frontiers in Immunology ISSN: 1664-3224 Article type: Review Article Received on: 24 Apr 2012 Accepted on: 15 Jul 2012 Provisional PDF published on: 15 Jul 2012 Frontiers website link: www.frontiersin.org Citation: Kluger N, Ranki A and Krohn K(2012) APECED: Is this a model for failure of T-cell and B-cell tolerance?. 3:232. doi:10.3389/fimmu.2012.00232 Article URL: http://www.frontiersin.org/Journal/Abstract.aspx?s=1244& name=primary%20immunodeficiencies&ART_DOI=10.3389 /fimmu.2012.00232 (If clicking on the link doesn't work, try copying and pasting it into your browser.) Copyright statement: © 2012 Kluger, Ranki and Krohn. This is an open‐access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc. This Provisional PDF corresponds to the article as it appeared upon acceptance, after rigorous peer-review. Fully formatted PDF and full text (HTML) versions will be made available soon. 1 1 2 3 4 APECED: Is this a model for failure of T-cell and B-cell tolerance? 5 6 7 8 9 10 Nicolas Kluger1, Annamari Ranki1 and Kai Krohn2* 11 12 1Department of Dermatology, Allergology and Venereology, Institute of Clinical Medicine, 13 University of Helsinki, Skin and Allergy Hospital, Helsinki University Central Hospital, Helsinki, 14 Finland 2 15 Clinical Research Institute HUCH Ltd, Helsinki, Finland 16 17 18 19 20 *Corresponding author: Professor Kai Krohn, Salmentaantie 751, 36450 Salmentaka, Finland. E- 21 mail [email protected] 22 Phone number: +358-40-833 1366 23 Fax number: +358-9-4718 6500 24 25 Running title: APECED syndrome 26 27 Conflicts of interest: none declared 28 Grant support: The study was financially supported by the European Science Foundation (ESF) and 29 the Sigrid Juselius foundation (NK) 30 31 32 Word count: 6027 33 Figure :Figure: 1 34 Tables :Tables: 2 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 2 50 Abbreviations 51 AADC: aromatic L-amino acid decarboxylase 52 AD: Addison’s disease 53 AE: Autoimmune enteropathy 54 APS-1: Autoimmune polyendocrinopathy syndrome type 1 55 APECED: Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy 56 CMC: chronic mucocutaneous candidiasis 57 EECs: enteroendocrine cells 58 GI: gastro-intestinal 59 HP: Hypoparathyroidism 60 IPEX: Immune dysregulation, polyendocrinopathy, enteropathy and X-linked 61 IF: Intrinsic factor 62 IL-1: Interleukin-1 63 IL-17: Interleukin-17 64 IL-22: Interleukin-22 65 mTECs: thymic medullary epithelial cells 66 NALP-5: NACHT leucine-rich-repeat protein 5 67 PE : promiscuous expression 68 PTH : parathormone 69 SLE: systemic lupus erythematosus 70 TH : tyrosine hydroxylase 71 TPH :tryptophan hydroxylase 72 TRIMs: tripartite motif-containing proteins 73 TSA : tissue specific antigens 74 3 75 Summary 76 In APECED, the key abnormality is in the T-cell defect that may lead to tissue destruction chiefly 77 in endocrine organs. Besides, APECED is characterized by high-titer antibodies against a wide 78 variety of cytokines, that could partly be responsible for the clinical symptoms during APECED, 79 mainly chronic mucocutaneous candidiasis, and linked to antibodies against Th17 cells effector 80 molecules, IL-17 and IL-22. On the other hand, the same antibodies, together with antibodies 81 against type I interferons may prevent the patients from other immunological diseases, such as 82 psoriasis and systemic lupus erythematous. The same effector Th17 cells, present in the 83 lymphocytic infiltrate of target organs of APECED, could be responsible for the tissue destruction. 84 Here again, the antibodies against the corresponding effector molecules, anti-IL-17 and anti-IL-22 85 could be protective. The occurrence of several effector mechanisms (CD4+ Th17 cell and CD8+ 86 CTL and the effector cytokines IL-17 and IL-22), and simultaneous existence of regulatory 87 mechanisms (CD4+ Treg and antibodies neutralizing the effect of the effector cytokines) may 88 explain the polymorphism of APECED. Almost all the patients develop the characteristic 89 manifestations of the complex, but temporal course and severity of the symptoms vary 90 considerably, even among siblings. The autoantibody profile does not correlate with the clinical 91 picture. One could speculate that a secondary homeostatic balance between the harmful effector 92 mechanisms, and the favorable regulatory mechanisms, finally define both the extent and severity 93 of the clinical condition in the AIRE defective individuals. The proposed hypothesis that in 94 APECED, in addition to strong tissue destructive mechanisms, a controlling regulatory mechanism 95 does exist, allow us to conclude that APECED could be treated, and even cured, with 96 immunological manipulation. 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 4 124 Synopsis 125 126 Autoimmune polyendocrinopathy syndrome type 1 (APS-1), also called APECED (Autoimmune 127 polyendocrinopathy-candidiasis-ectodermal dystrophy) is a recessively inherited monogenic 128 condition, caused by mutations in both alleles of the AIRE-gene (Autoimmune regulator). The 129 clinical hallmarks of APECED are sequentially erupting failures of endocrine organs, but other 130 manifestations, such as enamel dysgenics’, keratoconjuctivitis and asplenia occur as well. The 131 phenotype varies in individual patients as to the time course and severity of the symptoms. 132 133 AIRE is normally expressed in the medullary epithelial as well as dendritic cells in the thymus and 134 is thought to be responsible for the promiscuous expression (PE) of tissue specific antigens (TSA). 135 This process in turn would lead to the destruction of potentially auto-reactive T-cells and their 136 escape from this central tolerance mechanism into the periphery and their target organs. However, 137 recent findings have shed light for alternate mechanisms of action. In thymus, it has been proposed 138 that AIRE is responsible for the proper development and differentiation of medullary epithelial 139 cells, rather than being a transcription factor regulating the expression of TSAs. Furthermore, in 140 addition of thymus, AIRE expression can also be seen, although in very few number, in cells 141 derived from the two other germinal layers, mesoderm and ectoderm and AIRE protein can be seen 142 by immunofluorescence in some rare cells in peripheral lymphatic tissue and in the basal cells of 143 epidermis. This extra-thymic expression may be linked to the non-endocrine lesions seen in 144 APECED. 145 146 Finally, during the recent years, two new immunological mechanisms have been shown to operate 147 in APECED. The level of regulatory T-cells, characterized by the FOXP3 gene, is low in the 148 APECED patients. Furthermore, in addition to organ specific antibodies, APECED patients have 149 autoantibodies to a large series of different cytokines, the most frequently occurring being those 150 recognizing type 1 interferons and the product of Th17 cells, IL-17 and IL-22. Antibodies to the 151 last two are thought to be responsible for the chronic candidiasis, but in general, these cytokine 152 antibodies could also be protective, forming a balance mechanism to counter the effect of the 153 effector molecule. 154 155 In summary, both T-cell and B-cell products seem to be responsible for the various clinical signs 156 and symptoms in APECED. In an effort to balance these detrimental immunological mechanisms, 157 there seems to be again both T- and B-cell linked mechanisms, the regulatory T-cells and anti- 158 cytokine antibodies. 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 5 175 Introduction: 176 Autoimmune polyendocrinopathy syndrome, type 1 (APS-1) or autoimmune polyendocrinopathy– 177 candidiasis–ectodermal dystrophy syndrome (APECED; OMIM 240300) is a rare recessively 178 inherited disorder [1-4]. It is caused by mutations in the autoimmune regulator (AIRE) gene located 179 on locus 21q22.3 [5-7]. APECED displays a worldwide distribution, but specific clusters of high 180 prevalence of the disease are observed among Finns (1 : 25 000) [8] and Sardinians 1(1 : 14 500) 181 [9,10]. It is characterized by the variable association of autoimmune endocrine 182 (hypoparathyroidism, Addison’s disease, hypothyroidism, gonadal insufficiency, insulin-dependent 183 diabetes mellitus, atrophic gastritis and Biermer’s disease) and non-endocrine disorders (keratitis, 184 malabsorption, vitiligo, alopecia areata) and a specific predisposition to chronic mucocutaneous 185 candidiasis (CMC). A definite diagnosis of APECED is made upon one of the following criteria: i) 186 the presence of at least two of three major clinical features: CMC, hypoparathyroidism (HP) and 187 Addison's disease (AD), or ii) one disease component if a sibling has already a definite diagnosis or 188 iii) disease-causing mutations in both alleles of the AIRE gene. However, APECED being highly 189 variable in its presentation, the classical triad may be complete only after years of evolution and 190 diagnose may be therefore missed. Besides, APECED may appear during adolescence or in the 191 young adult [4]. Therefore, criteria for a probable APECED have been defined as follows: i) 192 presence of one of CMC, HP, AD (before 30 years of age) and at least one of the minor components 193 chronic diarrhea, keratitis, periodic rash with fever, severe constipation, autoimmune hepatitis, 194 vitiligo, alopecia, enamel hypoplasia, ii) any component and anti-interferon antibodies or iii) any 195 component and antibodies against NALP5 , AADC, TPH or TH [4]. 196 197 From circulating auto-immune antibodies to AIRE, FOXP3, APECED and IPEX 198 199 Our knowledge of the nature of the condition now called APS-1 or APECED has increased 200 simultaneously with the general development of immunology and autoimmunity.
Load more

Recommended publications
  • Abstracts from the 9Th Biennial Scientific Meeting of The
    International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):15 DOI 10.1186/s13633-017-0054-x MEETING ABSTRACTS Open Access Abstracts from the 9th Biennial Scientific Meeting of the Asia Pacific Paediatric Endocrine Society (APPES) and the 50th Annual Meeting of the Japanese Society for Pediatric Endocrinology (JSPE) Tokyo, Japan. 17-20 November 2016 Published: 28 Dec 2017 PS1 Heritable forms of primary bone fragility in children typically lead to Fat fate and disease - from science to global policy a clinical diagnosis of either osteogenesis imperfecta (OI) or juvenile Peter Gluckman osteoporosis (JO). OI is usually caused by dominant mutations affect- Office of Chief Science Advsor to the Prime Minister ing one of the two genes that code for two collagen type I, but a re- International Journal of Pediatric Endocrinology 2017, 2017(Suppl 1):PS1 cessive form of OI is present in 5-10% of individuals with a clinical diagnosis of OI. Most of the involved genes code for proteins that Attempts to deal with the obesity epidemic based solely on adult be- play a role in the processing of collagen type I protein (BMP1, havioural change have been rather disappointing. Indeed the evidence CREB3L1, CRTAP, LEPRE1, P4HB, PPIB, FKBP10, PLOD2, SERPINF1, that biological, developmental and contextual factors are operating SERPINH1, SEC24D, SPARC, from the earliest stages in development and indeed across generations TMEM38B), or interfere with osteoblast function (SP7, WNT1). Specific is compelling. The marked individual differences in the sensitivity to the phenotypes are caused by mutations in SERPINF1 (recessive OI type obesogenic environment need to be understood at both the individual VI), P4HB (Cole-Carpenter syndrome) and SEC24D (‘Cole-Carpenter and population level.
    [Show full text]
  • Repercussions of Inborn Errors of Immunity on Growth☆ Jornal De Pediatria, Vol
    Jornal de Pediatria ISSN: 0021-7557 ISSN: 1678-4782 Sociedade Brasileira de Pediatria Goudouris, Ekaterini Simões; Segundo, Gesmar Rodrigues Silva; Poli, Cecilia Repercussions of inborn errors of immunity on growth☆ Jornal de Pediatria, vol. 95, no. 1, Suppl., 2019, pp. S49-S58 Sociedade Brasileira de Pediatria DOI: https://doi.org/10.1016/j.jped.2018.11.006 Available in: https://www.redalyc.org/articulo.oa?id=399759353007 How to cite Complete issue Scientific Information System Redalyc More information about this article Network of Scientific Journals from Latin America and the Caribbean, Spain and Journal's webpage in redalyc.org Portugal Project academic non-profit, developed under the open access initiative J Pediatr (Rio J). 2019;95(S1):S49---S58 www.jped.com.br REVIEW ARTICLE ଝ Repercussions of inborn errors of immunity on growth a,b,∗ c,d e Ekaterini Simões Goudouris , Gesmar Rodrigues Silva Segundo , Cecilia Poli a Universidade Federal do Rio de Janeiro (UFRJ), Faculdade de Medicina, Departamento de Pediatria, Rio de Janeiro, RJ, Brazil b Universidade Federal do Rio de Janeiro (UFRJ), Instituto de Puericultura e Pediatria Martagão Gesteira (IPPMG), Curso de Especializac¸ão em Alergia e Imunologia Clínica, Rio de Janeiro, RJ, Brazil c Universidade Federal de Uberlândia (UFU), Faculdade de Medicina, Departamento de Pediatria, Uberlândia, MG, Brazil d Universidade Federal de Uberlândia (UFU), Hospital das Clínicas, Programa de Residência Médica em Alergia e Imunologia Pediátrica, Uberlândia, MG, Brazil e Universidad del Desarrollo,
    [Show full text]
  • Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency
    Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD, David A. Khan, MD, Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD, David I. Bernstein, MD, Joann Blessing-Moore, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Chief Editor: Francisco A. Bonilla, MD, PhD Co-Editor: David A. Khan, MD Members of the Joint Task Force on Practice Parameters: David I. Bernstein, MD, Joann Blessing-Moore, MD, David Khan, MD, David Lang, MD, Richard A. Nicklas, MD, John Oppenheimer, MD, Jay M. Portnoy, MD, Christopher R. Randolph, MD, Diane Schuller, MD, Sheldon L. Spector, MD, Stephen Tilles, MD, Dana Wallace, MD Primary Immunodeficiency Workgroup: Chairman: Francisco A. Bonilla, MD, PhD Members: Zuhair K. Ballas, MD, Javier Chinen, MD, PhD, Michael M. Frank, MD, Joyce T. Hsu, MD, Michael Keller, MD, Lisa J. Kobrynski, MD, Hirsh D. Komarow, MD, Bruce Mazer, MD, Robert P. Nelson, Jr, MD, Jordan S. Orange, MD, PhD, John M. Routes, MD, William T. Shearer, MD, PhD, Ricardo U. Sorensen, MD, James W. Verbsky, MD, PhD GlaxoSmithKline, Merck, and Aerocrine; has received payment for lectures from Genentech/ These parameters were developed by the Joint Task Force on Practice Parameters, representing Novartis, GlaxoSmithKline, and Merck; and has received research support from Genentech/ the American Academy of Allergy, Asthma & Immunology; the American College of Novartis and Merck.
    [Show full text]
  • SUPPLEMENTARY MATERIAL Effect of Next
    SUPPLEMENTARY MATERIAL Effect of Next-Generation Exome Sequencing Depth for Discovery of Diagnostic Variants KKyung Kim1,2,3†, Moon-Woo Seong4†, Won-Hyong Chung3, Sung Sup Park4, Sangseob Leem1, Won Park5,6, Jihyun Kim1,2, KiYoung Lee1,2*‡, Rae Woong Park1,2* and Namshin Kim5,6** 1Department of Biomedical Informatics, Ajou University School of Medicine, Suwon 443-749, Korea 2Department of Biomedical Science, Graduate School, Ajou University, Suwon 443-749, Korea, 3Korean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-806, Korea, 4Department of Laboratory Medicine, Seoul National University Hospital College of Medicine, Seoul 110-799, Korea, 5Department of Functional Genomics, Korea University of Science and Technology, Daejeon 305-806, Korea, 6Epigenomics Research Center, Genome Institute, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-806, Korea http//www. genominfo.org/src/sm/gni-13-31-s001.pdf Supplementary Table 1. List of diagnostic genes Gene Symbol Description Associated diseases ABCB11 ATP-binding cassette, sub-family B (MDR/TAP), member 11 Intrahepatic cholestasis ABCD1 ATP-binding cassette, sub-family D (ALD), member 1 Adrenoleukodystrophy ACVR1 Activin A receptor, type I Fibrodysplasia ossificans progressiva AGL Amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase Glycogen storage disease ALB Albumin Analbuminaemia APC Adenomatous polyposis coli Adenomatous polyposis coli APOE Apolipoprotein E Apolipoprotein E deficiency AR Androgen receptor Androgen insensitivity
    [Show full text]
  • The Potential Use of Intestinal Stem Cells to Treat Patients with Intestinal Failure
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by eScholarship - University of California UCLA UCLA Previously Published Works Title Concise Review: The Potential Use of Intestinal Stem Cells to Treat Patients With Intestinal Failure. Permalink https://escholarship.org/uc/item/1qr6h03t Journal Stem cells translational medicine, 6(2) ISSN 2157-6564 Authors Hong, Sung Noh Dunn, James CY Stelzner, Matthias et al. Publication Date 2016-09-16 DOI 10.5966/sctm.2016-0153 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Tissue Engineering and Regenerative Medicine TISSUE ENGINEERING AND REGENERATIVE MEDICINE Concise Review: Review: The The Potential Potential Use Use of of Intestinal Intestinal Stem Stem Cells to to Treat Treat Patients Patients with With Intestinal Intestinal Failure Failure aDivision of Gastroenterology SUNG NOH HONG,a,b JAMES C.Y. DUNN,c MATTHIAS STELZNER,d,e MART´IN G. MART´INa and Nutrition, Department of Pediatrics, Mattel Children’s Key Words. Intestinal failure x Congenital diarrhea x Microvillus inclusion disease x x Hospital and David Geffen Congenital tufting enteropathy Intestinal stem cell School of Medicine, University of California Los ABSTRACT Angeles, Los Angeles, California, USA; bDepartment Intestinal failure is a rare life-threatening condition that results in the inability to maintain normal of Medicine, Samsung growth and hydration status by enteral nutrition alone. Although parenteral nutrition and whole or- Medical Center, gan allogeneic transplantation have improved the survival of these patients, current therapies are associated with a high risk for morbidity and mortality. Development of methods to propagate adult Sungkyunkwan University human intestinal stem cells (ISCs) and pluripotent stem cells raises the possibility of using stem cell- School of Medicine, Seoul, c based therapy for patients with monogenic and polygenic forms of intestinal failure.
    [Show full text]
  • Statistical Analysis Plan
    Cover Page for Statistical Analysis Plan Sponsor name: Novo Nordisk A/S NCT number NCT03061214 Sponsor trial ID: NN9535-4114 Official title of study: SUSTAINTM CHINA - Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin in subjects with type 2 diabetes Document date: 22 August 2019 Semaglutide s.c (Ozempic®) Date: 22 August 2019 Novo Nordisk Trial ID: NN9535-4114 Version: 1.0 CONFIDENTIAL Clinical Trial Report Status: Final Appendix 16.1.9 16.1.9 Documentation of statistical methods List of contents Statistical analysis plan...................................................................................................................... /LQN Statistical documentation................................................................................................................... /LQN Redacted VWDWLVWLFDODQDO\VLVSODQ Includes redaction of personal identifiable information only. Statistical Analysis Plan Date: 28 May 2019 Novo Nordisk Trial ID: NN9535-4114 Version: 1.0 CONFIDENTIAL UTN:U1111-1149-0432 Status: Final EudraCT No.:NA Page: 1 of 30 Statistical Analysis Plan Trial ID: NN9535-4114 Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin in subjects with type 2 diabetes Author Biostatistics Semaglutide s.c. This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant parties.This
    [Show full text]
  • Autoimmune Polyendocrine Syndromes
    The new england journal of medicine review article medical progress Autoimmune Polyendocrine Syndromes George S. Eisenbarth, M.D., Ph.D., and Peter A. Gottlieb, M.D. From the Barbara Davis Center for Child- he autoimmune polyendocrine syndromes are diverse, and hood Diabetes, University of Colorado their diversity is a characteristic that is both clinically important and instruc- Health Sciences Center, Denver. Address re- t 1-4 print requests to Dr. Eisenbarth at the Bar- tive when their basic immunologic features are considered (Table 1). These bara Davis Center for Childhood Diabetes, syndromes include monogenic disorders (such as autoimmune polyendocrine syn- University of Colorado Health Sciences Cen- drome type I, which has classic and characteristic disease associations5) and complex ter, 4200 E. Ninth Ave., Box B140, Denver, CO 80262, or at george.eisenbarth@uchsc. genetic disorders (such as autoimmune polyendocrine syndrome type II, in which the 6 edu. component diseases are more variable ). Some of the component disorders are common (e.g., thyroid autoimmunity and celiac disease), whereas others are rare (e.g., Addison’s N Engl J Med 2004;350:2068-79. Copyright © 2004 Massachusetts Medical Society. disease and myasthenia gravis). Some of the disorders are usually asymptomatic (e.g., celiac disease); others are symptomatic but typically diagnosed after years of illness (Addison’s disease, which features severe fatigue and nausea, and pernicious anemia, which causes neuropathic symptoms); and still others are clinically dramatic at the time of diagnosis (type 1A diabetes, also known as immune-mediated diabetes and formerly called insulin-dependent diabetes). The term “polyendocrine” itself is a misnomer, in that not all patients have multiple endocrine disorders, and many have nonendocrine autoimmune diseases.
    [Show full text]
  • Abstracts Arch Dis Child: First Published As 10.1136/Archdischild-2012-302724.0957 on 1 October 2012
    Abstracts Arch Dis Child: first published as 10.1136/archdischild-2012-302724.0957 on 1 October 2012. Downloaded from antituberculosis therapy and fever resolved after 45 days. A nurse is É Karaszi, K Kalocsai, K Kardics, Z Liptai, A Trethon. Pediatric Infectology, St. László going to her house daily to check the patient’s adherence during the Hospital, Budapest, Hungary one year treatment. Background and Aims A ten year-old girl with hyper IgE syn- drome caused by DOCK8 mutation was admitted to our hospital due to neuropsychiatric symptoms. Cranial MRI revealed multifo- cal cerebral lesions. Our aim was to clarify the etiology of these lesions by extended microbiology tests and comprehensive search in the literature then provide her with proper treatment options. Methods Multiple blood and cerebrospinal fluid samples and were examined for bacterial and fungal culture, Aspergillus and Crypto- coccus antigen, HSV, CMV, Mycobacterium and Toxoplasma PCR, panfungal PCR and for Toxocara and E. hystolytica serology. Brain biopsy was also done for histology, bacterial and fungal culture. Results All diagnostic assays showed negative results therefore causative agents could not be identified For treatment, ceftriaxon and metronidazole combination was initially used accompanied by slight clinical and neuroradiological progression. Considering the possible presence of vascular brain lesions, high dose paren- teral steroid treatment was introduced together with preemptive parenteral voriconazol therapy. Further progression in the clini- cal and radiological status was observed. Although there is no Abstract 953 Figure 1 Chest radiography of miliary tuberculosis report of cerebral toxoplasmosis in this disorder, empirical anti- toxoplasma treatment was initiated with significant clinical Conclusion The diagnosis of MT can be clearly invoked with a improvement and radiological regression after 6-week therapy.
    [Show full text]
  • Allogeneic Hematopoietic Cell Transplantation for Genetic Diseases and Acquired Anemias
    MEDICAL POLICY POLICY TITLE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR GENETIC DISEASES AND ACQUIRED ANEMIAS POLICY NUMBER MP-9.055 Original Issue Date (Created): 10/1/2014 Most Recent Review Date (Revised): 2/24/2021 Effective Date: 8/1/2021 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY I. POLICY Allogeneic hematopoietic cell transplantation is considered medically necessary for select patients with the following disorders: Hemoglobinopathies Sickle cell anemia for children or young adults with either a history of prior stroke or at increased risk of stroke or end-organ damage. Homozygous β -thalassemia (i.e., thalassemia major Bone marrow failure syndromes Aplastic anemia including hereditary (including Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond, Diamond-Blackfan) or acquired (e.g., secondary to drug or toxin exposure) forms. Primary immunodeficiencies Absent or defective T cell function (e.g., severe combined immunodeficiency, Wiskott- Aldrich syndrome, X-linked lymphoproliferative syndrome) Absent or defective natural killer function (e.g. Chediak-Higashi syndrome) Absent or defective neutrophil function (e.g. Kostmann syndrome, chronic granulomatous disease, leukocyte adhesion defect) (See Policy Guideline # 1.) Inherited metabolic disease Lysosomal and peroxisomal storage disorders except Hunter, Sanfilippo, and Morquio syndromes (See Policy Guideline # 2) Page 1 MEDICAL POLICY POLICY TITLE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR GENETIC DISEASES AND ACQUIRED ANEMIAS POLICY NUMBER MP-9.055 Genetic disorders affecting skeletal tissue Infantile malignant osteopetrosis (Albers-Schonberg disease or marble bone disease) POLICY GUIDELINES Guideline 1 The following lists the immunodeficiencies that have been successfully treated by allogeneic hematopoietic cell transplantation (allo-HCT) (Gennery & Cant et al, 2008).
    [Show full text]
  • Primary Immune Regulatory Disorders and Targeted Therapies REVIEW
    Kolukısa B. and Barış S: Immune Dysregulation and Therapies REVIEW DOI: 10.4274/tjh.galenos.2021.2020.0724 Turk J Hematol 2021;38:1-14 Primary Immune Regulatory Disorders and Targeted Therapies Primer İmmün Regülatuvar Hastalıklar ve Hedeflenmiş Tedaviler Burcu Kolukısa1,2,3, Safa Barış1,2,3 1Marmara University Faculty of Medicine, Division of Pediatric Allergy and Immunology, İstanbul, Turkey 2İstanbul Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, İstanbul, Turkey 3The Işıl Berat Barlan Center for Translational Medicine, İstanbul, Turkey Abstract Öz Primary immune regulatory disorders (PIRDs) are a group of Primer immündisregülasyon hastalıkları (PİRH), immün sistemin diseases belonging to inborn errors of immunity. They usually doğuştan gelen bozuklukları içerisinde yer alan bir grup hastalıktır. exhibit lymphoproliferation, autoimmunities, and malignancies, Çoğunlukla lenfoproliferasyon, otoimmünite ve malignite bulguları with less susceptibility to recurrent infections. Unlike classical sergilerler ve bu grupta tekrarlayan enfeksiyonlara yatkınlık daha primary immune deficiencies, autoimmune manifestations, such as az olabilmektedir. Ayrıca diğer klasik primer immün yetmezliklerden cytopenias, enteropathy can be the first symptom of diseases, and farklı olarak otoimmün bulgular (örneğin; sitopeniler, enteropati) they are typically resistant to treatment. Increasing awareness of hastalığın ilk semptomu olarak çıkabilmekte ve tipik olarak tedaviye PIRDs among specialists and a multidisciplinary team approach would direnç gösterebilmektedir. Primer immün disregülasyon hastalıkları provide early diagnosis and treatment that could prevent end-organ hakkındaki farkındalığın artırılması ve multidisipliner yaklaşımlar, damage related to the diseases. In recent years, many PIRDs have been erken tanı ve tedaviyi mümkün kılarak, hastalıkla ilişkili gelişebilecek described, and understanding the immunological pathways linked to uç-organ hasarlarını önlemeye yardımcı olabilecektir.
    [Show full text]
  • Utviklingsavvik V02
    2/1/2021 Utviklingsavvik v02 Avdeling for medisinsk genetikk Utviklingsavvik Genpanel, versjon v02 * Enkelte genomiske regioner har lav eller ingen sekvensdekning ved eksomsekvensering. Dette skyldes at de har stor likhet med andre områder i genomet, slik at spesifikk gjenkjennelse av disse områdene og påvisning av varianter i disse områdene, blir vanskelig og upålitelig. Disse genetiske regionene har vi identifisert ved å benytte USCS segmental duplication hvor områder større enn 1 kb og ≥90% likhet med andre regioner i genomet, gjenkjennes (https://genome.ucsc.edu). For noen gener ligger alle ekson i områder med segmentale duplikasjoner: ACTB, ACTG1, ASNS, ATAD3A, CA5A, CFC1, CLCNKB, CYCS, DDX11, GBA, GJA1, MSTO1, PIGC, RBM8A, RPL15, SBDS, SDHA, SHOX, SLC6A8 Vi gjør oppmerksom på at ved identifiseringav ekson oppstrøms for startkodon kan eksonnummereringen endres uten at transkript ID endres. Avdelingens websider har en full oversikt over områder som er affisert av segmentale duplikasjoner. ** Transkriptets kodende ekson. Ekson Gen Gen affisert (HGNC (HGNC Transkript Ekson** Fenotype av symbol) ID) segdup* AAAS 13666 NM_015665.6 1-16 Achalasia-addisonianism-alacrimia syndrome, 231550 AARS 20 NM_001605.2 2-21 Epileptic encephalopathy, early infantile, 29 616339 AARS2 21022 NM_020745.4 1-22 Combined oxidative phosphorylation deficiency 8, 614096 AASS 17366 NM_005763.4 2-24 Hyperlysinaemia (Disorders of histidine, tryptophan or lysine metabolism) ABAT 23 NM_020686.6 2-16 GABA transaminase deficiency (Disorders of neurotransmitter metabolism, gamma-aminobutyrate)
    [Show full text]
  • Gross Deletions in TCOF1 Are a Cause of Treacher–Collins–Franceschetti Syndrome
    European Journal of Human Genetics (2012) 20, 769–777 & 2012 Macmillan Publishers Limited All rights reserved 1018-4813/12 www.nature.com/ejhg ARTICLE Gross deletions in TCOF1 are a cause of Treacher–Collins–Franceschetti syndrome Michael Bowman1, Michael Oldridge1, Caroline Archer1, Anthony O’Rourke1, Joanna McParland2, Roel Brekelmans3, Anneke Seller1 and Tracy Lester*,1 Treacher–Collins–Franceschetti syndrome (TCS) is an autosomal dominant craniofacial disorder characterised by midface hypoplasia, micrognathia, downslanting palpebral fissures, eyelid colobomata, and ear deformities that often lead to conductive deafness. A total of 182 patients with signs consistent with a diagnosis of TCS were screened by DNA sequence and dosage analysis of the TCOF1 gene. In all, 92 cases were found to have a pathogenic mutation by sequencing and 5 to have a partial gene deletion. A further case had a novel in-frame deletion in the alternatively spliced exon 6A of uncertain pathogenicity. The majority of the pathogenic sequence changes were found to predict premature protein termination, however, four novel missense changes in the LIS1 homology motif at the 5¢ end of the gene were identified. The partial gene deletions of different sizes represent B5.2% of all the pathogenic TCOF1 mutations identified, indicating that gene rearrangements account for a significant proportion of TCS cases. This is the first report of gene rearrangements resulting in TCS. These findings expand the TCOF1 mutation spectrum indicating that dosage analysis should be performed
    [Show full text]